Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells ; volume:10 ; number:1 ; day:4 ; month:1 ; year:2024 ; pages:1-13 ; date:12.2024
Cell death discovery ; 10, Heft 1 (4.1.2024), 1-13, 12.2024
- Creator
-
Todesca, Luca Matteo
Gerke, Matthias
Bulk, Emma Etmar
Bachmann, Magdalena
Rudersdorf, Alisa
Antonuzzo, Lorenzo
Pillozzi, Serena
Düfer, Martina
Szabo, Ildiko
Schwab, Albrecht
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41420-023-01776-5
- URN
-
urn:nbn:de:101:1-2024031910142096296354
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Todesca, Luca Matteo
- Gerke, Matthias
- Bulk, Emma Etmar
- Bachmann, Magdalena
- Rudersdorf, Alisa
- Antonuzzo, Lorenzo
- Pillozzi, Serena
- Düfer, Martina
- Szabo, Ildiko
- Schwab, Albrecht
- SpringerLink (Online service)
Other Objects (12)
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
Functional expression of mitochondrial KCa3.1 channels in non-small cell lung cancer cells
Cell-Cell Channels
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
KCa channel blockers increase effectiveness of the EGF receptor TK inhibitor erlotinib in non-small cell lung cancer cells (A549)
Deubiquitylase OTUD1 confers Erlotinib sensitivity in non-small cell lung cancer through inhibition of nuclear translocation of YAP1
Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer
The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
Functional expression of mitochondrial KCa3.1 channels in non-small cell lung cancer cells
Cell-Cell Channels
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
KCa channel blockers increase effectiveness of the EGF receptor TK inhibitor erlotinib in non-small cell lung cancer cells (A549)
Deubiquitylase OTUD1 confers Erlotinib sensitivity in non-small cell lung cancer through inhibition of nuclear translocation of YAP1
Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer
The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
Functional expression of mitochondrial KCa3.1 channels in non-small cell lung cancer cells
Cell-Cell Channels
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
KCa channel blockers increase effectiveness of the EGF receptor TK inhibitor erlotinib in non-small cell lung cancer cells (A549)
Deubiquitylase OTUD1 confers Erlotinib sensitivity in non-small cell lung cancer through inhibition of nuclear translocation of YAP1
Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer